Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.
Adult
Aged
Aged, 80 and over
Disease Progression
Female
Fluorescein Angiography
/ methods
Follow-Up Studies
Fundus Oculi
Humans
Macula Lutea
/ pathology
Male
Middle Aged
Prognosis
Retinal Pigment Epithelium
/ pathology
Retinal Telangiectasis
/ diagnosis
Retinal Vessels
/ pathology
Time Factors
Tomography, Optical Coherence
/ methods
Visual Acuity
OCT
MacTel
ellipsoid zone
en face image
macular telangiectasia type 2
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
12
09
2018
accepted:
14
03
2019
pubmed:
11
4
2019
medline:
6
2
2020
entrez:
11
4
2019
Statut:
ppublish
Résumé
To investigate the progression characteristics of ellipsoid zone (EZ) loss in eyes with macular telangiectasia type 2 (MacTel) as reflected by area and linear measurements, and their relevance for visual acuity. Participants were selected from the MacTel Study cohort. Linear and area measurements of EZ loss were performed in Spectral-Domain Optical Coherence Tomograph (SD-OCT) volume scans. Progression characteristics and correlations between linear and area measurements were analysed using linear mixed effects models. A total of 134 eyes of 70 patients were included (85 eyes with follow-up, mean 4.7 years, range: 1.4-8 years). Ellipsoid zone (EZ) loss significantly progressed at a mean annual increment of 0.057 mm Ellipsoid zone (EZ) loss in MacTel has a non-linear progression characteristic, and its rate depends on area size at baseline, which must be taken into account at sample selection in clinical trials. Our results show a good correlation of linear and area measures of EZ loss and a segregation of best-corrected visual acuity by EZ location, which may help routine clinical practice.
Identifiants
pubmed: 30968592
doi: 10.1111/aos.14110
pmc: PMC6785352
mid: NIHMS1019436
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e998-e1005Subventions
Organisme : Melbourne International Research Scholarship
Organisme : Intramural NIH HHS
ID : Z99 EY999999
Pays : United States
Organisme : UCL Institute of Ophthalmology
Organisme : Victoria State Government Operational Infrastructure Support
Organisme : National Institute for Health Research (NIHR)
Organisme : NIHR Biomedical Research Centre at Moorfields Eye Hospital
Organisme : Australian Government NHMRC IRIISS
Organisme : Lowy Medical Research Institute
Investigateurs
Sophie Bakri
(S)
Paul S Bernstein
(PS)
Barbara Blodi
(B)
Alexander Brucker
(A)
Felicitas Bucher
(F)
Mina Chung
(M)
Grant Comer
(G)
Ian Constable
(I)
Michael Cooney
(M)
Diana Do
(D)
Jacque Duncan
(J)
Catherine Egan
(C)
Michael J Elman
(MJ)
Amani Fawzi
(A)
Martin Friedlander
(M)
Alain Gaudric
(A)
Mark C Gillies
(MC)
Roger Goldberg
(R)
Joseph M Googe
(JM)
Robyn Guymer
(R)
Patrick Higgins
(P)
Frank Holz
(F)
Odette Houghton
(O)
Carel B Hoyng
(CB)
Jean-Pierre Hubschman
(JP)
Chirag Jhaveri
(C)
Arshad Khanani
(A)
David Lally
(D)
Cecilia Lee
(C)
Michael Lee
(M)
Joan W Miller
(JW)
Daniel Miller
(D)
Joseph Moisseiev
(J)
Robert Murphy
(R)
Raja Narayanan
(R)
Sandeep Randhawa
(S)
Paul V Raphaelian
(PV)
Ryan Rich
(R)
Richard Rosen
(R)
Philip Rosenfeld
(P)
Joke Ruys
(J)
Jose-Alain Sahel
(JA)
Steven Schwartz
(S)
Lawrence Singerman
(L)
Scott Sneed
(S)
Gisele Soubrane
(G)
Johannes R Vingerling
(JR)
David Warrow
(D)
David Weinberg
(D)
Sebastian Wolf
(S)
Charles Wykoff
(C)
Jiong Yan
(J)
Lawrence A Yannuzzi
(LA)
Stanislav A Zhuk
(SA)
Informations de copyright
© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Arch Ophthalmol. 1968 Nov;80(5):592-605
pubmed: 5684308
Ophthalmic Epidemiol. 2010 Jan-Feb;17(1):66-73
pubmed: 20100102
Retina. 2018 Jan;38 Suppl 1:S8-S13
pubmed: 28505012
Retina. 2015 Apr;35(4):742-9
pubmed: 25412037
Arch Ophthalmol. 1982 May;100(5):769-80
pubmed: 7082207
J Vis. 2005 Aug 17;5(7):632-9
pubmed: 16231998
Retina. 2018 Jan;38 Suppl 1:S20-S26
pubmed: 28541959
Retina. 2018 Jan;38 Suppl 1:S43-S50
pubmed: 29095354
Ophthalmology. 2010 Dec;117(12):2407-16
pubmed: 20678804
Vision Res. 2017 Mar;132:53-61
pubmed: 27286921
Am J Ophthalmol. 2015 Apr;159(4):659-666.e1
pubmed: 25528956
Retina. 2018 Jan;38 Suppl 1:S79-S88
pubmed: 28644304
Retina. 2015 Dec;35(12):2619-26
pubmed: 26340529
Invest Ophthalmol Vis Sci. 1990 Oct;31(10):2099-105
pubmed: 2211007
Invest Ophthalmol Vis Sci. 2012 Nov 29;53(12):7889-95
pubmed: 23092925
Retina. 2018 Jan;38 Suppl 1:S33-S42
pubmed: 28654458
Ophthalmology. 1993 Oct;100(10):1536-46
pubmed: 8414413
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO291-BIO299
pubmed: 28973315
Am J Ophthalmol. 2007 Mar;143(3):463-72
pubmed: 17239336
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1172-7
pubmed: 18326746
Invest Ophthalmol Vis Sci. 2012 Sep 25;53(10):6568-75
pubmed: 22899764
Ophthalmic Epidemiol. 2013 Apr;20(2):109-13
pubmed: 23510315
Invest Ophthalmol Vis Sci. 2012 Sep 14;53(10):6145-52
pubmed: 22899757
Ophthalmology. 2013 Nov;120(11):2344-52
pubmed: 23769334
Nat Genet. 2017 Apr;49(4):559-567
pubmed: 28250457
Arch Ophthalmol. 2006 Oct;124(10):1410-9
pubmed: 17030708
Prog Retin Eye Res. 2013 May;34:49-77
pubmed: 23219692